Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61984 | 0.65 | ATM (0.41) | ATMNPC1RAB9A | |
| SCHEMBL253244 | 0.65 | ATM (0.41) | ATMNPC1RAB9A | |
| SCHEMBL51544 | 0.65 | ATM (0.41) | ATMNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL10501335 | 0.64 | ATM (0.40) | ATMNPC1RAB9A | |
| SCHEMBL5894538 | 0.64 | ATM (0.44) | ATMNPC1RAB9A | |
| SCHEMBL3535166 | 0.63 | ATM (0.48) | ATMNPC1RAB9A | |
| SCHEMBL4620642 | 0.63 | ATM (0.48) | ATMNPC1RAB9A | |
| SCHEMBL5259264 | 0.63 | ATM (0.48) | ATMNPC1RAB9A | |
| SCHEMBL4559941 | 0.63 | ATM (0.48) | ATMNPC1RAB9A | |
| SCHEMBL11701434 | 0.63 | ATM (0.42) | ATMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 630 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114901646-B | Benzotriazine bisoxides and pharmaceutical compositions thereof | 浙江瑞臻医药有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-4385996-A2 | NOVEL SPIROBICYCLIC ANALOGUES | JANSSEN Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | disclosed |
| US-11993614-B2 | Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-28 | — | — | US | disclosed |
| US-20240124493-A1 | Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| EP-3720865-B1 | NOVEL SPIROBICYCLIC ANALOGUES | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-13 | — | — | EP | disclosed |
| US-11918576-B2 | Combination of an FGFR inhibitor and a CMET inhibitor | ASTEX THERAPEUTICS LTD (GB) | 2024-03-05 | — | — | US | disclosed |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| US-20240000778-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE | ASTEX THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-20230303612-A1 | Novel Spirobicyclic Analogues | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-28 | — | — | US | disclosed |
| WO-1994022816-A1 | METAL CHELATING COMPOUNDS | AMERSHAM INTERNATIONAL PLC (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0618191-A1 | Metal chelating compounds | AMERSHAM INTERNATIONAL plc (GB) | 1994-10-05 | — | — | EP | disclosed |
| US-5175287-A | Lower alkyl nitrite under reductive deamination | S R I INTERNATIONAL (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0478545-A4 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0478545-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1992-04-08 | — | — | EP | disclosed |
| WO-1991004028-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0413706-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989008647-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1989-09-21 | — | — | WO | disclosed |
| WO-1988002366-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1988-04-07 | — | — | WO | disclosed |
| US-4247691-A | ANIMAL GROWTH PROMOTERS, VETERINARY DISEASE CONTROLLER | CIBA-GEIGY CORPORATION (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918576-B2 | Combination of an FGFR inhibitor and a CMET inhibitor | FGFR3, FGFR1, FGFR2 | ATM 2398/4885NPC1 1430/4885RAB9A 3820/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | ATM 684/4885NPC1 2820/4885RAB9A 2454/4885 |
| US-20230303612-A1 | Novel Spirobicyclic Analogues | PRMT5, SIRT5, HDAC5 | ATM 1648/4885NPC1 2934/4885RAB9A 1624/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | ATM 724/4885NPC1 2681/4885RAB9A 2442/4885 |
| US-20240000778-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE | DPYD, NQO2, KRAS | ATM 3772/4885NPC1 812/4885RAB9A 2059/4885 |
| US-11993614-B2 | Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT1, PRMT8 | ATM 973/4885NPC1 2214/4885RAB9A 3145/4885 |
| US-20240124493-A1 | Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | PRMT5, PRMT1, PRMT8 | ATM 1003/4885NPC1 2440/4885RAB9A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.